Taking these findings together, the current study suggests that PD-L1 blockade in tumor-draining lymph nodes is one of the possible mechanisms of action by which TC0 and IC0 tumors respond to anti-PD-L1 therapy in clinical studies. The gene discussed is CD274; the disease is neoplasm.